# Diffuse Alveolar Haemorrhage {#sec-dah}

Potentially life-threatening hypoxaemic respiratory failure characterised by:

* Haemoptysis
* Anaemia
* Diffuse alveolar infiltrates


## Epidemiology and Risk Factors

## Pathophysiology

### Aetiology

Precipitants include:

* **Pulmonary capillaritis** secondary to autoimmune disease, including:
	* Systemic vasculitis
		* Granulomatosis with Polyangiitis
		* Churg-Strauss syndrome
		* Microscopic polyangiitis
	* Primary immune complex-mediated vasculitis
		* Goodpasture's syndrome
		* Henoch-Schonlein purpura
	* Secondary vasculitis
		* SLE
		* RA
		* APS
		* Mixed connective tissue disease
		* POlymyositis
		* Dermatomyositis
	* Essential cryoglobulinaemia
	* Behcet's disease
	* Anti-GBM disease
* Coagulation disorders
* Pulmonary vascular disease
	* MS
	* Pulmonary veno-occulisive disease
* Drugs
	* Amiodarone
	* Nitrofurantoin
	* Chemotherapeutics
	* Propylthiouracil
* Toxins
* Transplantation
	* BMT
* ARDS


## Assessment

Presentation typically with:

* Fever
* Dyspnoea
* Cough\
Haemoptysis is rare.
* Blood alveolar lavage samples

### History

### Exam

### Investigations

**Bedside**:

**Laboratory**:

:::column-margin
{{< include /includes/rheumatoid_screen.qmd >}}
:::

* Blood
	* FBE
	* Coagulation screen
	* Rheumatoid screen

**Imaging**:

:::column-margin
![Diffuse Alveolar Haemorrhage](/resources/dah.jpg)
:::

* CXR
* High-resolution CT Chest

**Other**:

* BAL\
Essential for diagnosis, and to exclude infection.

### Diagnostic Approach and DDx


## Management

:::priority
* Treat underlying cause
* **Immunosuppression**\
Corticosteroids as first line therapy.
:::

**Resuscitation**:

* A
	* Intubation and mechanical ventilation

**Specific therapy**:

* Pharmacological
	* Corticosteroids
		* Methylprednisolone 500mg Q6H for 4-5 days, followed by taper
	* Other immunosuppressants may be indicated
		* Methotrexate
		* MMF
		* Etanercept
* Procedural
	* Plasmapheresis\
	If indicated for the primary immunological precipitant, e.g. Goodpasture's or vasculitis.
* Physical

**Supportive care**:

**Disposition**:

**Preventative**:


### Marginal and Ineffective Therapies

## Anaesthetic Considerations

## Complications

* Death

## Prognosis

## Key Studies


---

## References

1. Park MS. [Diffuse Alveolar Hemorrhage](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3651925/). Tuberc Respir Dis (Seoul). 2013 Apr;74(4):151â€“62. 
1. Case courtesy of Jan Frank Gerstenmaier. [Radiopaedia.org](https://radiopaedia.org). From the case: rID: [28582](https://radiopaedia.org/cases/28582?lang=us).
